Patient Solutions (1-833-223-2428)
TAKING
ENJAYMO
ENJAYMO dosing
The ENJAYMO dosing schedule is designed to provide a continuous level of medicine.
- ENJAYMO is given as an intravenous (IV) infusion weekly for the first 2 weeks, and then every 2 weeks thereafter
- Your dose of ENJAYMO (either 6.5 g or 7.5 g) is based on your body weight, and your doctor will determine the dose that is right for you
Once weekly for the first 2 weeks
Every 2 weeks thereafter
Once weekly for the first 2 weeks
Every 2 weeks thereafter
It is important to me that I prioritize my ENJAYMO infusions every 2 weeks. While some people might think that’s a pain to work it into my schedule, I think of it as an investment in my health.
—LYNN, LIVING WITH COLD AGGLUTININ DISEASE (CAD)
Managing Cold Agglutinin Disease (CAD)
Chronic conditions like Cold Agglutinin Disease are serious, disrupting and hitting pause on your life. While ongoing treatment may sometimes feel like a burden, it's empowering to remember the benefits that can be achieved from consistent treatment with ENJAYMO.
Setting treatment goals
Make sure to arrive for your infusion on time and do not miss an appointment. If more than 17 days pass between ENJAYMO infusions, you will need to receive ENJAYMO weekly for 2 weeks before returning to an infusion schedule of every 2 weeks thereafter. If you miss an ENJAYMO infusion, call your doctor right away.
Hear from real people with Cold Agglutinin Disease like Duffy, Helen, and Gloria. Treatment with ENJAYMO helped them resume many of their favorite activities with the burden of Cold Agglutinin Disease symptoms such as fatigue being reduced. Whatever your treatment goals are, know that it may be possible to hit resume with ENJAYMO. Individual treatment results will vary.
Have any questions about dosing?
You can find more information by connecting with our team.
What to expect: the ENJAYMO infusion experience
My infusions are now every 2 weeks. We review my most recent lab results, then an IV is started while the pharmacist prepares the infusion, and I receive the infusion of ENJAYMO over an hour. When the infusion is complete, they observe me for another hour to ensure there is no adverse reaction.
—NANCY, LIVING WITH COLD AGGLUTININ DISEASE (CAD)
Get answers and take a closer look at what your ENJAYMO treatment could look like.
Your treatment journey
The infusion process can vary depending on individual needs, but below is an example of what you may expect. Be sure to speak with your healthcare provider about questions you may have.
Before your first infusion
- Talk to your doctor about any medical conditions, your medications, and any tests or vaccinations you’ll require before and while on treatment
What to expect during your first infusion—and future visits
- On the day of your infusion, a member of your treatment team will bring your ENJAYMO to room temperature
- A healthcare provider will administer ENJAYMO through a vein by intravenous infusion. The process will last between 1 to 2 hours
- After your infusion, you'll be monitored for infusion and allergic reactions by your treatment team for at least 2 hours on your first visit, and for at least 1 hour after all future infusions
Stick to your treatment plan
- Arrive for your infusion on time and do not miss an appointment. If more than 17 days pass between ENJAYMO infusions, you will need to receive ENJAYMO weekly for 2 weeks before returning to an infusion schedule of every 2 weeks thereafter
- If you miss an ENJAYMO infusion, call your doctor right away
Infusion tips and tricks
Treatment time can vary slightly from patient to patient, but your infusion session will typically last from 1 to 2 hours, plus additional time for your healthcare team to monitor you following your infusion.
During your treatment, it’s recommended you bring:
A list of your healthcare providers and medications you're taking
Your blood lab cards to remind your healthcare team to keep your blood warm
A blanket and/or comfortable clothing to keep you warm
Water and snacks in case you need them
Entertainment: book, games, laptop/tablet, phone, and chargers
I was going to a hospital to get my infusions initially, and now, if you can believe this… I started getting home infusions.
——DUFFY, LIVING WITH COLD AGGLUTININ DISEASE (CAD)
Interested in home infusions?
When considering treatment with ENJAYMO, the infusion process can feel daunting. Receiving ENJAYMO infusion at home by a nurse may be possible for you at no cost. Home infusion plans are an excellent way to receive treatment with more convenience and comfort.
Enroll in Recordati Rare Diseases Patient Solutions (RRD PS) to find out how. Talk to your HCP to see if home infusions may be right for you.
What is ENJAYMO?
ENJAYMO® is a prescription medicine used to treat the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).
It is not known if ENJAYMO is safe and effective in children.
IMPORTANT SAFETY INFORMATION
Do not receive ENJAYMO if you are allergic to sutimlimab-jome or any of the ingredients in ENJAYMO.
ENJAYMO can cause serious side effects, including:
- Serious Infections: ENJAYMO is a prescription medicine that affects your immune system. ENJAYMO may lower the ability of your immune system to fight infections. ENJAYMO increases your chance of getting serious infections including those caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B. These serious infections may quickly become life-threatening or cause death if not recognized and treated early.
- You must complete or be up to date with the vaccines against Streptococcus pneumoniae and Neisseria meningitidis at least 2 weeks before your first dose of ENJAYMO.
- If your healthcare provider decides that urgent treatment with ENJAYMO is needed, you should receive vaccinations as soon as possible.
- If you have been vaccinated against these bacteria in the past, you might need additional vaccines before starting ENJAYMO. Your healthcare provider will decide if you need additional vaccines.
- Vaccines do not prevent all infections caused by encapsulated bacteria. Call your healthcare provider or get emergency medical care right away if you get any of these signs and symptoms of a serious infection: fever with or without shivers or chills, fever with chest pain and cough, fever with high heart rate, headache and fever, confusion, clammy skin, fever and a rash, fever with breathlessness or fast breathing, headache with nausea or vomiting, headache with stiff neck or stiff back, body aches with flu-like symptoms, and/or eyes sensitive to light.
- Infusion-related reactions: Treatment with ENJAYMO may cause infusion-related reactions, including allergic reactions that may be serious or life-threatening. Your healthcare provider may slow down or stop your ENJAYMO infusion if you have an infusion-related reaction and will treat your symptoms if needed. Tell your healthcare provider right away if you develop symptoms during your ENJAYMO infusion that may mean you are having an infusion-related reaction, including: shortness of breath, decrease in blood pressure, chest discomfort, rapid heartbeat, nausea, injection site reaction, flushing, headache, dizziness, rash, and itchy skin.
- Risk of autoimmune disease: ENJAYMO may increase your risk for developing an autoimmune disease such as systemic lupus erythematosus (SLE). Tell your healthcare provider and get medical help if you develop any symptoms of SLE, including: joint pain or swelling, rash on the cheeks and nose, and unexplained fever.
- If you have CAD and you stop receiving ENJAYMO, your healthcare provider should monitor you closely for return of your symptoms after you stop ENJAYMO. Stopping ENJAYMO may cause the breakdown of your red blood cells due to CAD to return. Symptoms or problems that can happen due to red blood cell breakdown include: tiredness, shortness of breath, rapid heart rate, and blood in your urine or dark urine.
The most common side effects of ENJAYMO include: increase in blood pressure, urinary tract infection, respiratory tract infection, bacterial infection, swelling in lower legs or hands, joint pain, headache, nausea, runny nose, bluish color to the lips and skin, dizziness, feeling tired or weak, cough, and changes in color or sensation in the fingers and toes (Raynaud’s phenomenon).
These are not all the possible side effects of ENJAYMO. Call your doctor for medical advice about side effects. You are encouraged to report side effects of prescription drugs to the FDA. Call 1-800-FDA-1088 or visit www.fda.gov/medwatch.
Before receiving ENJAYMO, tell your healthcare provider about all of your medical conditions, including if you: have a fever or infection, including a history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; have an autoimmune disease such as systemic lupus erythematosus, also known as lupus; are pregnant or plan to become pregnant. It is not known if ENJAYMO will harm your unborn baby; are breastfeeding or plan to breastfeed. It is not known if ENJAYMO passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
